UK markets closed

Photocure ASA (0IMT.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
56.60+3.10 (+5.79%)
At close: 11:21AM BST

Photocure ASA

Hoffsveien 4
Oslo 0275
47 22 06 22 10

Full-time employees102

Key executives

NameTitlePayExercisedYear born
Mr. Daniel SchneiderPresident & CEON/AN/AN/A
Mr. Erik DahlChief Financial OfficerN/AN/A1957
Mr. David MoskowitzHead of Investor RelationsN/AN/AN/A
Anja Gossens-von der HeidtHead of Global Human ResourcesN/AN/AN/A
Dr. Anders Neijber M.D.Chief Medical Officer of Global Medical Affairs, Clinical Development and R&DN/AN/AN/A
Mr. Tolv HillestadGroup ControllerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.


Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.

Corporate governance

Photocure ASA’s ISS governance QualityScore as of 1 July 2024 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.